

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)				Complete if Known			
				Application Number	10/505,244		
				Filing Date	January 18, 2005		
				First Named Inventor	Kuwada		
				Group Art Unit	1614		
				Examiner Name	Pagonakis, Anna		
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
NON-PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
/A.P./	C1	Hu <i>et al.</i> , "An IκBα Inhibitor Causes Leukemia Cell Death through a p38 MAP Kinase-dependent, NF-κB-Independent Mechanism," <i>Cancer Res</i> 61:6290-6296, 2001					
/A.P./	C2	Cory <i>et al.</i> , "Implications of the Involvement of the Endoplasmic Reticulum Stress Pathway in Drug-Induced Apoptosis," <i>Anticancer Res</i> 28(2A):681-686, 2008					
/A.P./	C3	Vega <i>et al.</i> , "Rituximab-Induced Inhibition of YY1 and Bcl-x _L Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-x _L in Fas Resistance and Chemoresistance, Respectively," <i>J Immunol</i> 175:2174-2183, 2005					
/A.P./	C4	Huerta-Yepez <i>et al.</i> , "Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediates apoptosis via inactivation of NF-κB and inhibition of Bcl-x _L expression," <i>Oncogene</i> 23:4993-5003, 2004					
/A.P./	C5	Mabuchi <i>et al.</i> , "Inhibition of NF-κB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models," <i>J Biol Chem</i> 279:23477-23485, 2004					
/A.P./	C6	El-Rayes <i>et al.</i> , "Phase II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer," <i>Cancer Chemother Pharmacol</i> 61:283-289, 2008					
/A.P./	C7	Becerra <i>et al.</i> , "Increased Toxicity and Lack of Efficacy of Rofecoxib in Combination with Chemotherapy for Treatment of Metastatic Colorectal Cancer: A Phase II Study," <i>Int J Cancer</i> 105:868-872, 2003					
Examiner Signature: /Anna Pagonakis/				Date Considered: 11/26/2008			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							